Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ladislav Andera"'
Autor:
Simona Benesova, Ladislav Andera, Jiri Neuzil, Marie Ksandrova, Zuzana Nahacka, Martin Peterka, Jan Svadlenka
Publikováno v:
Biochimica et biophysica acta. Molecular cell research. 1865(3)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine that can trigger apoptosis in many types of human cancer cells via engagement of its two pro-apoptotic receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5). TRAIL can also activate
Autor:
Lan-Feng Dong, Jiri Neuzil, Lubomir Prochazka, Jaromira Chladova, Marina Stantic, Renata Zobalova, Xiu-Fang Wang, Stephen John Ralph, Ladislav Andera
Publikováno v:
Biochemical and Biophysical Research Communications. 355:855-859
Recent evidence suggests that a subset of cells within a tumour have 'stem-like' characteristics. These tumour-initiating cells, distinct from non-malignant stem cells, show low proliferative rates, high self-renewing capacity, propensity to differen
Autor:
Jan Zivny, Jaroslav Cermak, Emanuel Necas, Magdalena Plasilova, Tomas Stopka, Jaroslav Jelinek, Radana Neuwirtova, Ladislav Andera
Publikováno v:
Leukemia. 16:67-73
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, APO2L) has been shown to induce apoptosis in a number of tumor cell lines as well as in some primary tumors whereas cells from most normal tissues are highly resistant to TRAIL-induced a
Publikováno v:
APOPTOSIS. 7:179-187
The incidence of cancer and atherosclerosis, two most common causes of death in developed countries, has been stagnating or, even, increasing. Drugs effective against such conditions are needed and, in this regard, the potential anti-atherosclerotic
Autor:
K. Kothonidis, Alexander Pintzas, G. Zografos, George Nasioulas, Ladislav Andera, Eftychia Oikonomou
Publikováno v:
British Journal of Cancer 97:1(Jun2007):73-84
British Journal of Cancer
British Journal of Cancer
Most data on the therapeutic potential of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as well as resistance to FAS ligand (FASL) in colorectal cancer have come from in vitro studies using cell lines. To gain a clearer understandi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::381413a1e5357dbab53a6359e2fd8ad2
http://helios-eie.ekt.gr/EIE/handle/10442/2650
http://helios-eie.ekt.gr/EIE/handle/10442/2650
Autor:
Ludmila Dolezalova, Emanuel Necas, Zdenka Gasova, Jaroslav Cermak, Jan Molinsky, Tereza Simonova, Ladislav Andera, Sergiu Leahomschi, Pavel Klener, Jan Zivny
Publikováno v:
Blood cells, moleculesdiseases. 42(1)
TNF-related apoptosis-inducing ligand (TRAIL) is a proapoptotic cytokine implicated in cancer cell surveillance. A potential of TRAIL as a cancer-specific therapeutic agent has been proposed, either as a single agent or in combination with chemothera
Autor:
Nina Gellert, Michael P. Murphy, Battista Borghi, Jiri Neuzil, Renata Alleva, Christian Weber, Ladislav Andera, Marco Tomasetti
Publikováno v:
FEBS letters. 503(1)
Generation of free radicals is often associated with the induction and progression of apoptosis. Therefore, antioxidants can prove anti-apoptotic, and can help to elucidate specific apoptotic pathways. Here we studied whether coenzyme Q, present in m
Autor:
Elena M. Tchevkina, Olga Surova, Vitaliy O. Kaminskyy, Boris Zhivotovsky, Ladislav Andera, I. B. Zborovskaya, T Piskunova
Publikováno v:
Cell Death & Disease
TNF-related apoptosis-inducing ligand (TRAIL) is a promising cytokine for killing tumor cells. However, a number of studies have demonstrated that different cancer cells resist TRAIL treatment and, moreover, TRAIL can promote invasion and metastasis